Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

• Status: Unknown status
• Trial end date: 2013-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Sao Paulo
• Treatments: Adjuvants, Immunologic; Imiquimod; Immunologic Factors

Criteria

Inclusion Criteria:

• Patients whose injuries were confirmed by anatomical and pathological study (periocular superficial basal cell carcinoma).

• Patients with clinical counter indication for reconstructive surgery (high surgical risk).

• Patients who have refused a restorative surgery. (aesthetic reasons)

• Patients who have signed the free and informed consent.

Exclusion Criteria:

• Patients who have a hypersensitivity reaction to the formula components.

• Children under 12 years of age.

• Pregnant and breastfeeding women.

• Patients whose injury was not confirmed by anatomical and pathological study.

• Individuals with previous autoimmune or inflammatory disease.

• Patients who have refused to sign the free and informed term of consent.